Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. Patients and Samples
2.2. Development Cohort
Survival Analyses
2.3. Validation Cohort
Survival Analyses
2.4. Multivariate Analyses DC and VC
2.5. Detailed Analysis of Age Dependence
2.6. Test Reproducibility
2.7. Protein Set Enrichment Analysis (PSEA)
3. Discussion
4. Material and Methods
4.1. Cohorts and Patient Characteristics
4.2. Spectral Acquisition
4.3. Test Development
4.4. Protein Set Enrichment Analysis (PSEA)
4.5. Statistics
4.6. Data Availability
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Ledermann, J.A.; Raja, F.A.; Fotopoulou, C.; Gonzalez-Martin, A.; Colombo, N.; Sessa, C.; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018, 29, iv259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moore, K.; Colombo, N.; Scambia, G.; Kim, B.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; et al. Maintenance olaparib in Patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 2018, 379, 2495–2505. [Google Scholar] [CrossRef] [PubMed]
- Pignata, S.; Cecere, S.C.; du Bois, A.; Harter, P.; Heitz, F. Treatment of recurrent ovarian cancer. Ann. Oncol. 2017, 28, viii51–viii56. [Google Scholar] [CrossRef] [PubMed]
- Carvalho, V.P.; Grassi, M.L.; de Souza Palma, C.; Carrara, H.H.A.; Faça, V.M.; Candido dos Reis, F.J.; Poersch, A. The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers. Transl. Res. 2019, 206, 71–90. [Google Scholar] [CrossRef]
- Lee, J.M.; Kohn, E.C. Proteomics as a guiding tool for more effective personalized therapy. Ann. Oncol. 2010, 21 (Suppl. 7), vii205–vii210. [Google Scholar] [CrossRef]
- Kobel, M.; Kalloger, S.E.; Boyd, N.; McKinney, S.; Mehl, E.; Palmer, C.; Leung, S.; Bowen, N.J.; Ionescu, D.N.; Rajput, A.; et al. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med. 2008, 5, e232. [Google Scholar] [CrossRef]
- Sajic, T.; Liu, Y.; Aebersold, R. Using data-independent, high-resolution mass spectrometry in protein biomarker research: Perspectives and clinical applications. Proteom. Clin. Appl. 2015, 9, 307–321. [Google Scholar] [CrossRef]
- Swiatly, A.; Horala, A.; Hajduk, J.; Matysiak, J.; Nowak-Markwitz, E.; Kokot, Z.J. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer. BMC Cancer 2017, 17, 472. [Google Scholar] [CrossRef]
- Russell, M.R.; Walker, M.J.; Williamson, A.J.; Gentry-Maharaj, A.; Ryan, A.; Kalsi, J.; Skates, S.; D’Amato, A.; Dive, C.; Pernemalm, M.; et al. Protein Z: A putative novel biomarker for early detection of ovarian cancer. Int. J. Cancer 2016, 138, 2984–2992. [Google Scholar] [CrossRef] [Green Version]
- Swiatly, A.; Horala, A.; Matysiak, J.; Hajduk, J.; Nowak-Markwitz, E.; Kokot, Z.J. Understanding ovarian cancer: ITRAQ-Based proteomics for biomarker discovery. Int. J. Mol. Sci. 2018, 19, 2240. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Z.; Bast, R.C., Jr.; Yu, Y.; Li, J.; Sokoll, L.J.; Rai, A.J.; Rosenzweig, J.M.; Cameron, B.; Wang, Y.Y.; Meng, X.; et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882–5890. [Google Scholar] [CrossRef] [Green Version]
- Ueland, F.R.; Desimone, C.P.; Seamon, L.G.; Miller, R.A.; Goodrich, S.; Podziwlinski, I.; Sokoll, L.; Smith, A.; van Nagell, J.R., Jr.; Zhang, Z. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet. Gynecol. 2011, 117, 1289–1297. [Google Scholar] [CrossRef]
- Zhang, Z.; Chan, D.W. The road from discovery to clinical diagnostics: Lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol. Biomark. Prev. 2010, 19, 2995–2999. [Google Scholar] [CrossRef] [Green Version]
- Tsypin, M.; Asmellash, S.; Meyer, K.; Touchet, B.; Roder, H. Extending the information content of the MALDI analysis of biological fluids via multi-million shot analysis. PLoS ONE 2019, 14, e0226012. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roder, J.; Oliveira, C.; Net, L.; Tsypin, M.; Linstid, B.; Roder, H. A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data. BMC Bioinform. 2019, 20, 325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roder, H.; Oliveira, C.; Net, L.; Linstid, B.; Tsypin, M.; Roder, J. Robust identification of molecular phenotypes using semi-supervised learning. BMC Bioinform. 2019, 20, 273. [Google Scholar] [CrossRef] [Green Version]
- Chekerov, R.; Braicu, I.; Castillo-Tong, D.C.; Richter, R.; Cadron, I.; Mahner, S.; Woelber, L.; Marth, C.; can Gorp, T.; Speiser, P.; et al. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. Int. J. Gynecol. Cancer 2013, 23, 268–275. [Google Scholar] [CrossRef] [PubMed]
- Breiman, L.; Out-of-bag Estimation. Technical Report. Department of Statistics, University of California. 1996. Available online: https://www.stat.berkeley.edu/~breiman/OOBestimation.pdf (accessed on 26 May 2020).
- Wu, X.; Zhu, L.; Ma, P.C. Next-generation novel noninvasive cancer molecular diagnostics platforms beyond tissues. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 964–977. [Google Scholar] [CrossRef] [Green Version]
- Pignata, S.; Scambia, G.; Katsaros, D.; Gallo, C.; Pujade-Lauraine, E.; de Placido, S.; Bologna, A.; Weber, B.; Raspagliesi, F.; Panici, P.B.; et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014, 15, 396–405. [Google Scholar] [CrossRef]
- Varnier, R.; le Saux, O.; Chabaud, S.; Garin, G.; Sohier, E.; Wang, Q.; Paindavoine, S.; Pérol, D.; Baudet, C.; Attignon, V.; et al. Actionable molecular alterations in advanced gynaecologic malignancies: Updated results from the ProfiLER programme. Eur. J. Cancer 2019, 118, 156–165. [Google Scholar] [CrossRef]
- Gueugneau, M.; Coudy-Gandilhon, C.; Gourbeyre, O.; Chambon, C.; Cambaret, L.; Polge, C.; Taillandier, D.; Attaix, D.; Friguet, B.; Maier, A.; et al. Proteomics of muscle chronological ageing in post-menopausal women. BMC Genom. 2014, 15, 1165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lehallier, B.; Gate, D.; Schaum, N.; Nanasi, T.; Lee, S.E.; Yousef, H.; Moran Losada, P.; Berdnik, D.; Keller, A.; Verghese, J.; et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat. Med. 2019, 25, 1843–1850. [Google Scholar] [CrossRef]
- Calabrese, V.; Dattilo, S.; Petralia, A.; Parenti, R.; Pennisi, M.; Koverech, G.; Calabrese, V.; Graziano, A.; Monte, I.; Maiolino, L.; et al. Analytical approaches to the diagnosis and treatment of aging and aging-related disease: Redox status and proteomics. Free Radic. Res. 2015, 49, 511–524. [Google Scholar] [CrossRef]
- Emilsson, V.; Gudnason, V.; Jennings, L.L. Predicting health and life span with the deep plasma proteome. Nat. Med. 2019, 25, 1815–1816. [Google Scholar] [CrossRef] [PubMed]
- Suidan, R.S.; Ramirez, P.T.; Sarasohn, D.M.; Teitcher, J.B.; Iyer, R.B.; Zhou, Q.; Iasonos, A.; Denesopolis, J.; Zivanovic, O.; Long Rohcer, K.C.; et al. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol. Oncol. 2017, 145, 27–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shim, S.H.; Lee, S.J.; Kim, S.; Kim, S.; Kim, D.; Lee, J.J.; Kim, J.; Kim, Y.; Nam, J. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients. Gynecol. Oncol. 2015, 136, 30–36. [Google Scholar] [CrossRef]
- Taguchi, F.; Solomon, B.; Gregorc, V.; Roder, H.; Gray, R.; Kazuo, K.; Nishio, M.; Brahmer, J.; Spreafico, A.; Ludovini, V.; et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study. J. Natl. Cancer Inst. 2007, 99, 838–846. [Google Scholar] [CrossRef] [Green Version]
- Carbone, D.P.; Ding, K.; Roder, H.; Grigorieva, J.; Roder, J.; Tsao, M.; Seymour, L.; Shepherd, F.A. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J. Thorac. Oncol. 2012, 7, 1653–1660. [Google Scholar] [CrossRef] [Green Version]
- Gregorc, V.; Novello, S.; Lazzari, C.; Barni, S.; Aieta, M.; Mencoboni, M.; Grossi, F.; de Pas, T.; de Marinis, F.; Bearz, A.; et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): A biomarker-stratified, randomised phase 3 trial. Lancet Oncol. 2014, 15, 713–721. [Google Scholar] [CrossRef]
- Gadgeel, S.; Goss, G.; Soria, J.; Felip, E.; Georgoulias, V.; Lu, S.; Cobo, M.; Syrigos, K.; Lee, K.H.; Göker, E.; et al. Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung. Cancer 2017, 109, 101–108. [Google Scholar] [CrossRef] [Green Version]
- Fidler, M.J.; Fheid, C.; Roder, J.; Basu, S.; Sayidine, S.; Fughhu, I.; Pool, M.; Batus, M.; Bonomi, P.; Borgia, J.A. The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer 2018, 18, 310. [Google Scholar] [CrossRef] [PubMed]
- Matulonis, U.A.; Shapira-Frommer, R.; Santin, A.D.; Lisyanskaya, A.S.; Pignata, S.; Vergote, I.; Raspagliesi, F.; Sonke, G.S.; Birrer, M.; Provencher, D.M.; et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. Ann. Oncol. 2019, 30, 1080–1087. [Google Scholar] [CrossRef] [PubMed]
- Weber, J.S.; Sznol, M.; Sullivan, R.J.; Blackmon, S.; Boland, G.; Kluger, H.M.; Halaban, R.; Bacchiocchi, A.; Ascierto, P.; Capone, M.; et al. A Serum protein signature associated with outcome after Anti-PD-1 therapy in metastatic melanoma. Cancer Immunol. Res. 2018, 6, 79–86. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ascierto, P.A.; Capone, M.; Grimaldi, A.M.; Mallardo, D.; Simeone, E.; Madonna, G.; Roder, H.; Meyer, K.; ASmellash, S.; Oliveira, C.; et al. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. J. Immunother. Cancer 2019, 7, 91. [Google Scholar] [CrossRef]
- Kowanetz, M.; Leng, N.; Roder, J.; Oliveira, C.; Asmellash, S.; Meyer, K.; Roder, H.; Ballinger, M.; Zou, W.; Shames, D. Evaluation of immune-related markers in the circulating proteome and their association with atezolizumab efficacy in patients with 2L+ NSCLC. J. Immunother. Cancer 2018, 6 (Suppl. 1). [Google Scholar] [CrossRef] [Green Version]
- Afshar-Kharghan, V. The role of the complement system in cancer. J. Clin. Investig. 2017, 127, 780–789. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Zhang, Z.; Wang, J.; Zhang, X. Association between C-reactive protein level and subsequent risk of ovarian cancer: A meta-analysis of 13 cohorts in 1,852 ovarian cancer patients. Medicine 2020, 99, e18821. [Google Scholar] [CrossRef]
- Wang, Q.; Bian, C.E.; Peng, H.; He, L.; Zhao, X. Association of circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 with the risk of ovarian cancer: A systematic review and meta-analysis. Mol. Clin. Oncol. 2015, 3, 623–628. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Wang, Y.; Zhang, Z. Adipokine RBP4 drives ovarian cancer cell migration. J. Ovarian. Res. 2018, 11, 29. [Google Scholar] [CrossRef]
- Wu, J.; Fu, Z.; Liu, G.; Xu, P.; Xu, J.; Jia, X. Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis. Medicine 2017, 96, e7062. [Google Scholar] [CrossRef]
- Yamada, Y.Y.; Kawaguchi, R.; Iwai, K.; Niiro, E.; Morioka, S.; Tanase, Y.; Kobayashi, H. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer. J. Obst. Gyn. 2020, 40, 102–106. [Google Scholar] [CrossRef] [PubMed]
- Wu, H.; Li, R.; Zhang, Z.; Jiang, H.; Ma, H.; Yuan, C.; SUn, C.; Li, Y.; Kong, B. Kallistatin inhibits tumour progresion and platinum resistance in high grade serous ovarian cancer. J. Ovarian Res. 2019, 12, 125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aust, S.; Knogler, T.; Pils, D.; Obermayr, E.; Reinthaller, A.; Zahn, L.; Radlgruber, I.; Mayerhoefer, M.E.; Grimm, C.; Polterauer, S. Skeletal muscle depletion and markers for cancer cachexia are strong prognostic factors in epithelial ovarian cancer. PLoS ONE 2015, 10, e0140403. [Google Scholar] [CrossRef] [PubMed]
- Archid, R.; Solass, W.; Tempfer, C.; Königsrainer, A.; Adolph, M.; Reymond, M.A.; Wilson, R.B. Cachexia anorexia syndrome and associated metabolic dysfunction in peritoneal metastasis. Int. J. Mol. Sci. 2019, 20, 5444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pils, D.; Tong, D.; Hager, G.; Obermayr, E.; Aust, S.; Heinze, G.; Kohl, M.; Schuster, E.; Wolf, A.; Sehouli, J.; et al. A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer—A study of the OVCAD consortium. BMC Cancer 2013, 13, 178. [Google Scholar] [CrossRef] [Green Version]
- Swiatly, A.; Plewa, S.; Matysiak, J.; Kokot, Z.J. Mass spectrometry-based proteomics techniques and their application in ovarian cancer research. J. Ovarian. Res. 2018, 11, 88. [Google Scholar] [CrossRef]
- Grigorieva, J.; Asmellash, S.; Oliveira, C.; Roder, H.; Net, L.; Roder, J. Application of protein set enrichment analysis to correlation of protein functional sets with mass spectral features and multivariate proteomic tests. Clin. Mass Spectrom. 2020, 15, 44–53. [Google Scholar] [CrossRef]
- Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [Google Scholar] [CrossRef] [Green Version]
- Roder, J.; Linstid, B.; Oliveira, C. Improving the power of gene set enrichment analyses. BMC Bioinform. 2019, 20, 257. [Google Scholar] [CrossRef] [Green Version]
- Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 1995, 57, 289–300. [Google Scholar] [CrossRef]
- Muller, M.; Hummelink, K.; Hurkmans, D.P.; Niemeijer, A.-L.N.; Monkhorst, K.; Roder, J.; Oliveira, C.; Roder, H.; Aerts, J.G.; Smit, E.F. A serum protein classifier identifying patients with advanced non-small cell lung cancer who derive clinical benefit from treatment with immune checkpoint inhibitors. Clin. Cancer Res. 2020. [Google Scholar] [CrossRef] [PubMed]
- Breiman, L.; Bagging Predictors. Department of Statistics, University of California. 1996. Available online: https://link.springer.com/content/pdf/10.1007/BF00058655.pdf (accessed on 26 May 2020).
- Schapire, R.E. The Strength of Weak Learnability. Mach. Learning 1990, 5, 197–227. [Google Scholar] [CrossRef] [Green Version]
- Srivastava, N.; Hinton, G.; Krizhevsky, A.; Sutskever, I.; Salakhutdinov, R. Dropout: A Simple Way to Prevent Neural Network Overfitting. J. Mach. Learn. Res. 2014, 15, 1929–1958. [Google Scholar]
Characterstic | Development Cohort (n = 199) n (%) | Validation Cohort (n = 135) n (%) | |
---|---|---|---|
Histology | serous | 142 (71) | 113 (84) |
non-serous | 57 (29) | 22 (16) | |
FIGO | 1 | 36 (18) | 0 (0) |
2 | 7(4) | 8 (6) | |
3 | 119 (60) | 101 (75) | |
4 | 37 (19) | 26 (19) | |
Histologic | NA | 2 (1) | 0 (0) |
Grade | 1 | 11 (6) | 4 (3) |
2 | 81 (41) | 30 (22) | |
3 | 105 (53) | 101 (75) | |
Residual | yes | 83 (42) | 38 (28) |
Tumor | no | 113 (57) | 97 (72) |
NA | 3 (2) | 0 (0) | |
Age | ≤55 | 77 (39) | 58 (43) |
>55 | 122 (61) | 77 (57) | |
Median (range) | Median (range) | ||
Age | 59 (18–88) | 57 (27–85) |
Development Cohort | |||||
---|---|---|---|---|---|
OS | PFS | ||||
HR (95% CI) | p-Value | HR (95% CI) | p-Value | ||
Test Classification (vs. poor) | good | 0.23 (0.08–0.65) | 0.005 | 0.31 (0.12–0.79) | 0.014 |
FIGO (vs. IV) | I/II | 0.24 (0.06–1.02) | 0.054 | 0.12 (0.02–0.59) | 0.009 |
III | 0.70 (0.29–1.72) | 0.439 | 0.58 (0.25–1.36) | 0.209 | |
Histology (vs. serous) | non-serous | 1.15 (0.45–2.91) | 0.775 | 0.85 (0.31–2.33) | 0.749 |
Grade (vs. 3) | 1/2 | 0.76 (0.32–1.79) | 0.533 | 1.35 (0.63–2.88) | 0.440 |
Residual Tumor (vs. yes) | no | 1.19 (0.39–3.62) | 0.759 | 1.37 (0.48–3.87) | 0.559 |
Validation Cohort | |||||
OS | PFS | ||||
HR (95% CI) | p-value | HR (95% CI) | p-value | ||
Test Classification (vs. poor) | good | 0.43 (0.16–1.20) | 0.108 | 0.49 (0.23–1.06) | 0.0686 |
FIGO (vs. IV) | I/II | 0.14 (0.01–1.53) | 0.108 | 0.08 (0.01–0.55) | 0.010 |
III | 0.29 (0.09–0.92) | 0.036 | 0.25 (0.08–0.78) | 0.017 | |
Histology (vs. serous) | non-serous | 2.01 (0.61–6.60) | 0.249 | 1.44 (0.57–3.62) | 0.437 |
Grade (vs. 3) | 1/2 | 0.72 (0.24–2.12) | 0.548 | 0.49 (0.23–1.06) | 0.070 |
Residual Tumor (vs. yes) | no | 1.67 (0.63–4.43) | 0.305 | 0.80 (0.26–2.44) | 0.692 |
Development Cohort | |||||
---|---|---|---|---|---|
OS | PFS | ||||
HR (95% CI) | p-Value | HR (95% CI) | p-Value | ||
ProteomicAgeClassification | 0.68 (0.56–0.83) | <0.001 | 0.85 (0.73–1.00) | 0.047 | |
FIGO (vs. IV) | I/II | 0.17 (0.07–0.42) | <0.001 | 0.08 (0.03–0.21) | <0.001 |
III | 0.46 (0.28–0.75) | 0.002 | 0.51 (0.30–0.84) | 0.009 | |
Histology (vs. serous) | non-serous | 1.53 (0.94–2.48) | 0.087 | 1.71 (1.04–2.81) | 0.034 |
Grade (vs. 3) | 1/2 | 0.97 (0.62–1.50) | 0.881 | 1.35 (0.88–2.09) | 0.171 |
Residual Tumor (vs. yes) | no | 1.71 (1.06–2.77) | 0.028 | 1.67 (1.05–2.64) | 0.029 |
Validation Cohort | |||||
OS | PFS | ||||
HR (95% CI) | p-Value | HR (95% CI) | p-Value | ||
ProteomicAgeClassification | 0.81 (0.67–1.00) | 0.045 | 0.83 (0.70–0.98) | 0.030 | |
FIGO (vs. IV) | I/II | 0.62 (0.19–2.01) | 0.428 | 0.26 (0.07–0.94) | 0.040 |
III | 0.49 (0.28–0.84) | 0.010 | 0.56 (0.32–0.96) | 0.035 | |
Histology (vs. serous) | 0.88 (0.45–1.69) | 0.695 | 0.79 (0.43–1.46) | 0.458 | |
Grade (vs. 3) | 1/2 | 0.99 (0.56–1.76) | 0.981 | 0.95 (0.58–1.54) | 0.835 |
Residual Tumor (vs. yes) | no | 2.20 (1.33–3.65) | 0.002 | 1.74 (1.03–2.95) | 0.039 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kasimir-Bauer, S.; Roder, J.; Obermayr, E.; Mahner, S.; Vergote, I.; Loverix, L.; Braicu, E.; Sehouli, J.; Concin, N.; Kimmig, R.; et al. Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer. Cancers 2020, 12, 2519. https://doi.org/10.3390/cancers12092519
Kasimir-Bauer S, Roder J, Obermayr E, Mahner S, Vergote I, Loverix L, Braicu E, Sehouli J, Concin N, Kimmig R, et al. Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer. Cancers. 2020; 12(9):2519. https://doi.org/10.3390/cancers12092519
Chicago/Turabian StyleKasimir-Bauer, Sabine, Joanna Roder, Eva Obermayr, Sven Mahner, Ignace Vergote, Liselore Loverix, Elena Braicu, Jalid Sehouli, Nicole Concin, Rainer Kimmig, and et al. 2020. "Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer" Cancers 12, no. 9: 2519. https://doi.org/10.3390/cancers12092519